Brain Cannabinoid CB2 Receptor in Schizophrenia

Biological Psychiatry

Volumn 67, Issue 10, 2010, Pages 974-982

  Ishiguro, Hiroki ^a,b   Horiuchi, Yasue ^a,b   Ishikawa, Maya ^a   Koga, Minori ^a,b   Imai, Keiko ^a   Suzuki, Yoshimi ^a   Morikawa, Miyuki ^a   Inada, Toshiya ^c   Watanabe, Yuichiro ^d   Takahashi, Makoto ^d   Someya, Toshiyuki ^d   Ujike, Hiroshi ^e   Iwata, Nakao ^f   Ozaki, Norio ^g   Onaivi, Emmanuel S ^h   Kunugi, Hiroshi ⁱ   Sasaki, Tsukasa ^j   Itokawa, Masanari ^b,k,l   Arai, Makoto ^k   Niizato, Kazuhiro ^l   Iritani, Shyuji ^l   Naka, Izumi ^m   Ohashi, Jun ^a   Kakita, Akiyoshi ⁿ   Takahashi, Hitoshi ⁿ   Nawa, Hiroyuki ⁿ   Arinami, Tadao ^a,b   more..

^a UNIVERSITY OF TSUKUBA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c SEIWA HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h WILLIAM PATERSON UNIVERSITY   (United States)

ⁱ NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^l TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

^m UNIVERSITY OF TOKYO   (Japan)

ⁿ NIIGATA UNIVERSITY   (Japan)

more..

Author keywords

Association; cAMP; cannabinoid; G protein coupled receptor; gene; methamphetamine; MK 801; mouse; postmortem brain; schizophrenia

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR;

ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GENETIC TRANSFECTION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOCOMOTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BRAIN; CASE-CONTROL STUDIES; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDOLES; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB2; SCHIZOPHRENIA; STARTLE REACTION;

EID: 77951620284     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2009.09.024     Document Type: Article

References (45)

1. Andreasson S., Allebeck P., Engstrom A., and Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2 (1987) 1483-1486
2. Zammit S., Allebeck P., Andreasson S., Lundberg I., and Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ 325 (2002) 1199
3. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29 (2004) 2108-2114
4. Morgan C.J., and Curran H.V. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192 (2008) 306-307
5. Bangalore S.S., Prasad K.M., Montrose D.M., Goradia D.D., Diwadkar V.A., and Keshavan M.S. Cannabis use and brain structural alterations in first episode schizophrenia-A region of interest, voxel based morphometric study. Schizophr Res 99 (2008) 1-6
6. De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., and Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2 (2003) 5
7. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., and Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10 (1999) 1665-1669
8. Koethe D., Llenos I.C., Dulay J.R., Hoyer C., Torrey E.F., Leweke F.M., et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 114 (2007) 1055-1063
9. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 (1988) 605-613
10. Gerard C., Mollereau C., Vassart G., and Parmentier M. Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res 18 (1990) 7142
11. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
12. Hajos M., Hoffmann W.E., and Kocsis B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: Relevance to schizophrenia. Biol Psychiatry 63 (2008) 1075-1083
13. Chavarria-Siles I., Contreras-Rojas J., Hare E., Walss-Bass C., Quezada P., Dassori A., et al. Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147 (2008) 279-284
14. Leroy S., Griffon N., Bourdel M.C., Olie J.P., Poirier M.F., and Krebs M.O. Schizophrenia and the cannabinoid receptor type 1 (CB1): Association study using a single-base polymorphism in coding exon 1. Am J Med Genet 105 (2001) 749-752
15. Martinez-Gras I., Hoenicka J., Ponce G., Rodriguez-Jimenez R., Jimenez-Arriero M.A., Perez-Hernandez E., et al. (AAT)n repeat in the cannabinoid receptor gene, CNR1: Association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci 256 (2006) 437-441
16. Ujike H., Takaki M., Nakata K., Tanaka Y., Takeda T., Kodama M., et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7 (2002) 515-518
17. Hoffman H.S., and Ison J.R. Reflex modification in the domain of startle. I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 87 (1980) 175-189
18. Swerdlow N.R., Light G.A., Cadenhead K.S., Sprock J., Hsieh M.H., and Braff D.L. Startle gating deficits in a large cohort of patients with schizophrenia: Relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63 (2006) 1325-1335
19. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156 (2001) 234-258
20. Braff D.L., Light G.A., Ellwanger J., Sprock J., and Swerdlow N.R. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry 57 (2005) 817-820
21. Long L.E., Malone D.T., and Taylor D.A. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31 (2006) 795-803
22. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074 (2006) 514-536
23. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
24. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., et al. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res 1071 (2006) 10-23
25. Ishiguro H., Iwasaki S., Teasenfitz L., Higuchi S., Horiuchi Y., Saito T., et al. Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J 7 (2007) 380-385
26. Dixon A.L., Liang L., Moffatt M.F., Chen W., Heath S., Wong K.C., et al. A genome-wide association study of global gene expression. Nat Genet 39 (2007) 1202-1207
27. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25 (2003) 115-121
28. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: From mice to human subjects. PLoS ONE 3 (2008) e1640
29. Sipe J.C., Arbour N., Gerber A., and Beutler E. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: Possible risk for autoimmune disorders. J Leukoc Biol 78 (2005) 231-238
30. Errico F., Rossi S., Napolitano F., Catuogno V., Topo E., Fisone G., et al. D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. J Neurosci 28 (2008) 10404-10414
31. van den Buuse M., Wischhof L., Xi L.R., Martin S., and Karl T. Neuregulin 1 hypomorphic mutant mice: Enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. [published online ahead of print April 29]. Int J Neuropsychopharmacol (2009)
32. Gray L., McOmish C.E., Scarr E., Dean B., and Hannan A.J. Sensitivity to MK-801 in phospholipase C-beta1 knockout mice reveals a specific NMDA receptor deficit. [published online ahead of print February 23]. Int J Neuropsychopharmacol (2009)
33. Pearce B.D. Schizophrenia and viral infection during neurodevelopment: A focus on mechanisms. Mol Psychiatry 6 (2001) 634-646
34. Fruntes V., and Limosin F. Schizophrenia and viral infection during neurodevelopment: A pathogenesis model?. Med Sci Monit 14 (2008) RA71-RA77
35. Palazuelos J., Aguado T., Egia A., Mechoulam R., Guzman M., and Galve-Roperh I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 20 (2006) 2405-2407
36. Cabral G.A., and Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. Expert Rev Mol Med 11 (2009) e3
37. De la Fuente M., Llorente R., Baeza I., De Castro N.M., Arranz L., Cruces J., et al. Early maternal deprivation in rats: A proposed animal model for the study of developmental neuroimmunoendocrine interactions. Ann N Y Acad Sci 1153 (2009) 176-183
38. Ellenbroek B.A., van den Kroonenberg P.T., and Cools A.R. The effects of an early stressful life event on sensorimotor gating in adult rats. Schizophr Res 30 (1998) 251-260
39. Ellenbroek B.A., and Cools A.R. Early maternal deprivation and prepulse inhibition: The role of the postdeprivation environment. Pharmacol Biochem Behav 73 (2002) 177-184
40. Ellenbroek B.A., de Bruin N.M., van den Kroonenburg P.T., van Luijtelaar E.L., and Cools A.R. The effects of early maternal deprivation on auditory information processing in adult Wistar rats. Biol Psychiatry 55 (2004) 701-707
41. Garner B., Wood S.J., Pantelis C., and van den Buuse M. Early maternal deprivation reduces prepulse inhibition and impairs spatial learning ability in adulthood: No further effect of post-pubertal chronic corticosterone treatment. Behav Brain Res 176 (2007) 323-332
42. Lovic V., Fleming A.S., and Fletcher P.J. Early life tactile stimulation changes adult rat responsiveness to amphetamine. Pharmacol Biochem Behav 84 (2006) 497-503
43. Lopez-Gallardo M., Llorente R., Llorente-Berzal A., Marco E.M., Prada C., Di Marzo V., et al. Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: Gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation. Dev Neurobiol 68 (2008) 1429-1440
44. Llorente R., Llorente-Berzal A., Petrosino S., Marco E.M., Guaza C., Prada C., et al. Gender-dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: A possible role for the endocannabinoid system. Dev Neurobiol 68 (2008) 1334-1347
45. Suárez J., Llorente R., Romero-Zerbo S.Y., Mateos B., Bermúdez-Silva F.J., de Fonseca F.R., and Viveros M.P. Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB(1) and CB(2) cannabinoid receptors of neonatal rats. Hippocampus 19 (2009) 623-632